Rina-S Clinical Trials

4 actively recruiting trials across 4 locations

Also known as: GEN1184, PRO1184, Rinatabart Sesutecan, Rinatabart sesutecan

Pipeline

Phase 2: 1Phase 3: 2Phase 1/2: 1

Top Sponsors

Genmab4

Indications

Cancer4
Endometrial Cancer2
Lung Cancer2
Primary Refractory Ovarian Cancer1
Platinum Sensitive Ovarian Cancer (PSOC)1

Phoenix, Arizona1 trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

USOR HonorHealth

Phase 1/2

Miami, Florida1 trial

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Mt. Sinai Comprehensive Cancer Center

Phase 3

Sarasota, Florida1 trial

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

SMH - Sarasota - Main Campus

Phase 3

Fairfax, Virginia1 trial

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Virginia Cancer Specialists

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.